已核实 DOI PubMed 相关产品: 0

Natural Staurosporine Derivatives with Fluorescence for Cancer Theranostics

Journal 2025 · IF 3.4 · 发表于 2025 年 10 月 16 日
作者: Kualiang Li,Wei Liu,Tong Wu,Yongbo Wei,Ying Liu,Jingming Zhou,Li Chen,Jian Zhou,Yusheng Lu,Haipeng Xu,Lijun Xie
阅读全文 在 PubMed 查看

摘要

In recent years, developing effective theranostic agents for precise cancer treatment has been one of the most prevalent strategies. Herein, three staurosporine derivatives, MCY-STS, ECY-STS, and ICY-STS, synthesized through minor modifications of natural staurosporine, are reported. These derivatives not only exhibit attractive fluorescence properties, including solvatochromism and dual-state (solution and solid) emission, but also demonstrate potent protein kinase C inhibitory activity and anticancer effects against NCI-N87, MCF-7, and SK-OV-3 cell lines. Theoretical calculation analyses, including density functional theory calculations, molecular docking, and molecular dynamics simulations, are employed to elucidate their protein–ligand interactions and luminescence mechanisms. Further investigations reveal that ECY-STS significantly inhibits tumor growth while illuminating tumor tissues for therapy visualization. Collectively, these modified fluorescent staurosporine derivatives, particularly ECY-STS, represent promising theranostic agents that provide a novel strategy for cancer imaging and treatment in humans. Graphical The theranostic agent ECY-STS, derived from staurosporine, a bacterial PKC inhibitor, exhibits a distinct fluorescent signal at tumor sites upon injection. Targeting PKCθ, it preferentially accumulates in tumors and significantly suppresses tumor growth, demonstrating its potential as a novel theranostic agent.